Podcasts about Mahajan

In this episode, I connect with Reena Mahajan, founder of Paris-based Studio Divercity, to discuss creating people-centered and nature-based cities and reducing car dependency in cities around the globe. Studio Divercity envisions a world where people-centered & nature-positive cities replace car-centric urban sprawl. Reena is an architect, urban planner, and mobility advocate with a strong background in low-impact, water-sensitive, and sustainable urban development. Her story is yet another example of a parent radicalized into being a safe streets activist while trying to keep her young child safe from the violence posed by car drivers. We also gush a bit about the fabulous Paris School Streets program and street greening efforts.Thank you so much for tuning in! If you enjoyed this episode, please share it with a friend and subscribe to the podcast on your preferred listening platform. Also, don't forget to check out the Active Towns Channel for more video content.Helpful Links (note that some may include affiliate links to help me support the channel):- Studio DiverCity website- Tom Flood's Rovelo Creative website- My first episode w/ Tom Flood- My second episode w/ Tom Flood- My Paris 2015 car-free day videoIf you are a fan of the Active Towns Podcast, please consider supporting the effort as an Active Towns Ambassador in the following ways:1. Join our Patreon community. Contributions start at just $3 per month2. If you enjoyed this episode, you can also "leave a tip" through "Buy Me a Coffee"3. Make a donation to my non-profit, Advocates for Healthy Communities, Inc., to help support my pro bono work with citiesCredits:- Video and audio production by John Simmerman- Music via Epidemic SoundResources used during the production of this video:- My recording platform is Ecamm Live- Editing software Adobe Creative Cloud Suite- Equipment: Contact me for a complete listFor more information about the Active Towns effort or to follow along, please visit our links below:- Active Towns Website- Active Towns on Bluesky- Weekly Update e-NewsletterBackground:Hi Everyone! My name is John Simmerman, and I'm a health promotion and public health professional with over 30 years of experience. Over the years, my area of concentration has evolved into a specialization in how the built environment influences human behavior related to active living and especially active mobility.Since 2010,  I've been exploring, documenting, and profiling established, emerging, and aspiring Active Towns wherever they might be while striving to produce high-quality multimedia content to help inspire the creation of more safe and inviting, environments that promote a "Culture of Activity" for "All Ages & Abilities."The Active Towns Channel features my original video content and reflections, including a selection of podcast episodes and short films profiling the positive and inspiring efforts happening around the world as I am able to experience and document them.Thanks once again for tuning in! I hope you find this content helpful and insightful.Creative Commons License: Attributions, Non-Commercial, No Derivatives, 2025 ★ Support this podcast on Patreon ★

Send Maria a text HERE :) In this episode of The Small Nonprofit Podcast, Maria chats with Sheela Mahajan, founder of the Nonprofit Science Institute and host of the Nonprofit Science Podcast. Sheela shares how nonprofits can move beyond reactive decision-making and start thinking more strategically. They discuss the challenges of shifting organizational mindsets, how to implement systematic decision-making processes, and the importance of defining problems before jumping to solutions. Sheela introduces the Signals Framework, a structured approach to problem-solving that empowers nonprofit leaders to make data-driven decisions with confidence. Key Topics Covered: Why nonprofits struggle with decision-making Introducing the signals framework Rethinking fundraising events Overcoming resistance to change The power of documentation in decision-making Actionable tips: ➜ Use the signals framework: write down the specific problem you're solving, collect data, and test solutions systematically. ➜ Get everyone in the room: bring together staff, leadership, and board members to align on key challenges. ➜ Track decision-making: keep records of strategic decisions to help future teams stay informed. ➜ Shift the culture: encourage a data-driven mindset rather than relying on “this is how we've always done it.” ➜ Start small: test the framework on a single issue before applying it organization-wide. Resources: Nonprofit Science Institute – Website Nonprofit Science Podcast – Listen Here Free Ebook: The Signals Framework – Download Here Connect with Us: Connect with Maria Rio Connect with Sheela Mahajan Subscribe and Review: Don't forget to subscribe to The Small Nonprofit Podcast on your favorite platform! Leave a review to help us reach more listeners and continue providing valuable insights. Watch this episode on YouTube. Support the Podcast: Support these conversations by donating here. Coming Next Week: Join us next week for a must-listen episode on landing your dream nonprofit job!

In this enlightening episode we welcome back the highly esteemed Rebecca Edwards, Director of Education at Activated Probiotics, to dive into the emerging and critical topic of the oral microbiome. The conversation covers the fundamental aspects of the oral microbiome, its significant links to brain health, Alzheimer's disease, cardiovascular issues, pregnancy outcomes, immune health, and even COVID-19 predispositions. Rebecca reveals the frightening realities of oral bacteria, including the pathways through which oral health can influence systemic conditions like Alzheimer's and rheumatoid arthritis. The podcast also emphasises practical actions for maintaining oral hygiene, the role of diet and hydration, and the groundbreaking potential of oral probiotics. Additionally, the episode provides a sneak peek into the upcoming Activated Probiotics Symposium, featuring a stellar lineup of speakers and groundbreaking topics aimed at shifting paradigms in healthcare.EPISODE HIGHLIGHTS:03:19 The importance of oral hygiene03:51 Understanding the oral microbiome06:45 The oral microbiome and public health09:05 The rise of microbiome interest post-COVID16:25 The oral microbiome's impact on brain health24:43 The role of dental plaque and gum disease29:49 Oral health and systemic diseases35:34 Call to action for practitioners38:19 The impact of COVID on healthcare39:28 Oral health and genetic predispositions41:29 The importance of dental care accessibility42:48 Rethinking mouthwash and bacteria45:26 Diet and oral microbiome48:02 Cardiovascular health and oral hygiene53:19 Probiotics for oral health59:13 Practical tips for oral hygiene01:03:04 Upcoming probiotic symposiumTickets to Activated Probiotics Symposium here:https://events.humanitix.com/activated-probiotics-symposium-2025Activated Probiotics instagram:https://www.instagram.com/activatedprobiotics/References to the oral microbiome:Kanagasingam S, von Ruhland C, Welbury R, Singhrao S K. Antimicrobial, polarizing light, and paired helical filament properties of fragmented tau peptides of selected putative gingipains. J Alzheimers Dis 2022; doi: 10.3233/JAD-220486.Kanagasingam S, von Ruhland C, Welbury R, Chukkapalli S S, Singhrao S K. Porphyromonas gingivalis conditioned medium induces amyloidogenic processing of the amyloid-β Protein precursor upon in vitro infection of SH-SY5Y cells. J Alzheimers Dis Rep 2022; doi: 10.3233/ADR-220029.Haditsch U, Roth T, Rodriguez L, Hancock S, Cecere T, Nguyen M, Arastu-Kapur S, Broce S, Raha D, Lynch CC, Holsinger LJ, Dominy SS, Ermini F. Alzheimer's Disease-Like Neurodegeneration in Porphyromonas gingivalis Infected Neurons with Persistent Expression of Active Gingipains. J Alzheimers Dis. 2020;75(4):1361-1376. doi: 10.3233/JAD-200393. PMID: 32390638; PMCID: PMC7369049.Stephen S. Dominy et al. ,Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors.Sci. Adv.5,eaau3333(2019).DOI:10.1126/sciadv.aau3333The Oral-Gut-Brain AXIS: The Influence of Microbes in Alzheimer's DiseaseNarengaowa1, Wei Kong1, Fei Lan1, Umer Farooq Awan2, Hong Qing1* and Junjun Ni1*References to all 11 studies on Biome BreatheRanjith, A., Nazimudeen, N. Bin, & Baiju, K. V. (2022). Probiotic mouthwash as an adjunct to mechanical therapy in the treatment of stage II periodontitis: A randomized controlled clinical trial. International Journal of Dental Hygiene, 20(2), 415–421. https://doi.org/10.1111/idh.12589Doppalapudi, R., Vundavalli, S., & Prabhat, M. (2020). Effect of probiotic bacteria on oral Candida in head‑ and neck‑radiotherapy patients: A randomized clinical trial. Journal of Cancer Research and Therapeutics, 6(3), 470–477. https://doi.org/10.4103/jcrt.JCRTThakkar, P. K., Imranulla, M., Kumar, P. G. N., Prashant, G. M., Sakeenabi, B., & Sushanth, V. H. (2013). Effect of probiotic mouthrinse on dental plaque accumulation: A randomized controlled trial. Dentistry and Medical Research|, 1(1), 7–12.Purunaik, S., Thippeswamy, H. M., & Chavan, S. S. (2014). To Evaluate the Effect of Probiotic Mouthrinse on Plaque and Gingivitis among 15-16 Year Old School Children of Mysore City, India- Randomized Controlled Trial. Global Journal of Medical Research, 14(4), 9–14.Jothika, M., Vanajassun, Pp., & Someshwar, B. (2015). Effectiveness of probiotic, chlorhexidine and fluoride mouthwash against Streptococcus mutans - randomised, single-blind, in-vivo study. Journal of International Society of Preventive and Community Dentistry, 5(7), 44. https://doi.org/10.4103/2231-0762.156153Jindal, G., Pandey, R. K., Agarwal, J., & Singh, M. (2011). A comparative evaluation of probiotics on salivary mutans streptococci counts in Indian children. European Archives of Paediatric Dentistry, 12(4), 211–215. https://doi.org/10.1007/BF03262809Manikandan, S., Behera, S., Karthikeyan, R., Niranjana, A., Bharathan, R., & Mohammed, O. B. (2020). Effect of green tea extract mouthrinse and probiotic mouthrinse on salivary pH in a group of schoolchildren: An in vivo study. Journal of Pharmacy And Bioallied Sciences, 12(5), 404. https://doi.org/10.4103/jpbs.JPBS_119_20Jindal, V., Mahajan, N., Goel, A., Kaur, R., Mahajan, A., & Malhotra, P. (2017). Clinical efficacy of probiotic mouthwash in the treatment of gingivitis patients in Himachal population. Journal of the International Clinical Dental Research Organization, 9(1), 41. https://doi.org/10.4103/2231-0754.207386Deshmukh, M. A., Dodamani, A. S., Karibasappa, G., Khairnar, M. R., Naik, R. G., & Jadhav, H. C. (2017). Comparative evaluation of the efficacy of probiotic, herbal and chlorhexidine mouthwash on gingival health: A randomized clinical trial. Journal of Clinical and Diagnostic Research, 11(3), ZC13–ZC16. https://doi.org/10.7860/JCDR/2017/23891.9462Sharma, P., Datta, G., Gandhi, K., & Kumar, D. (2019). A comparative evaluation of efficacy of probiotic and chlorhexidine mouthrinses on gingival health and plaque accumulation in 6-9 year old children. International Journal of Applied Dental Sciences, 5(1), 156–162. http://www.oraljournal.com/archives/2019/5/1/C/5-1-43Doppalapudi, R., Vundavalli, S., & Prabhat, M. P. V. (2020). Effect of probiotic bacteria on oral Candida in head‑ and neck‑radiotherapy patients: A randomized clinical trial. Journal of Cancer Research and Therapeutics, 16, 470–477. https://doi.org/10.4103/jcrt.JCRT

* Israel approves plan to withdraw troops from Gaza: report Israel is moving forward with plans to withdraw its troops from Gaza, following progress in prisoner exchange talks with Hamas, according to media reports. Haaretz newspaper reported that the military has approved several withdrawal strategies aimed at swiftly pulling soldiers out of the area. One of the options being considered includes using the Netzarim Corridor, which splits Gaza into two, as a potential exit route. * Houthis claim another attack on US aircraft carrier in Red Sea The Houthis in Yemen say they've launched another attack on the USS Harry Truman aircraft carrier in the Red Sea. Their military spokesperson, Yahya Saree, stated that missiles and drones were used to target the ship in the northern Red Sea. He explained that the attack aimed to push the carrier out of its operational area. * Sudan paramilitary leader says 'lost' key Al-Jazirah state capital The leader of Sudan's Rapid Support Forces, or the RSF, has admitted that his troops have lost control of Wad Madani, the capital of Al-Jazirah state, after an army offensive. In a message to the paramilitaries and the public, Mohamed Hamdan Daglo vowed to retake the city, a key hub in central Sudan. The RSF had held it since December 2023. Meanwhile, the army, which has been fighting the RSF since April, announced on Saturday that it had entered Wad Madani and was clearing out "remnants of the rebels". * Ethiopia, Somalia restore full diplomatic relations Ethiopia and Somalia have decided to fully restore their diplomatic ties, a move the two nations announced in a joint statement. The announcement came after a meeting between Ethiopian Prime Minister Abiy Ahmed and Somali President Hassan Sheikh Mohamud, where they discussed ways to strengthen their relationship and address shared priorities. Back in April 2024, Somalia expelled Ethiopia's ambassador and shut down its consulates in Hargeisa, following tensions over the Somaliland port deal. The dispute was eventually resolved with the Ankara Declaration, brokered by Türkiye. * Toxic smoke from LA wildfires poses health risk People in Los Angeles are being urged to stay indoors as dangerous wildfire smoke spreads across the area. Massive fires burning in and around the city have filled the air with toxic fumes, creating health risks for residents. Anish Mahajan from the Los Angeles County Department of Public Health explained in a press conference that wildfire smoke contains a mix of fine particles, gases and water vapours. It's those small particles that can get into your nose and throat, causing sore throats and headaches, Mahajan said, advising caution for everyone—even those who are otherwise healthy.

Join us for a lively conversation with Aditi Mahajan as she reveals her secrets to creating stunning, color-infused artwork, her journey in the crafting community, and how being an Altenew Educator has shaped her creative process. Find out how her culture and her work as a psychologist inspires her style.Bring your card designs to life with the power of color! Join Chromatic Harmony Online Cardmaking Class https://altenew.com/products/chromatic-harmonyCraft your life with Altenew! Follow us for more design inspiration:Instagram: https://www.instagram.com/altenewllc/TikTok: https://www.tiktok.com/@altenewFacebook: https://www.facebook.com/altenewYouTube: https://www.youtube.com/altenewPinterest: https://www.pinterest.com/altenew/Card blog: https://www.blog.altenew.comScrapbook blog: https://www.mixedmedia.altenew.comCheck out Artistry by AltenewInstagram: https://www.instagram.com/artistrybyaltenew/YouTube: https://www.youtube.com/channel/UCCY0ifFqCq6irkxFZeQGrXgVisit https://www.altenew.com to shop for your crafting stash.Contact our Customer Happiness Team at support@altenew.com if you have any questions.

In the latest episode of the Discover Your SecondAct Podcast, we have a very special guest—RJ Ginnie AKA Ginnie Mahajan!Ginnie is an award-winning radio jockey and the beloved host of the morning show Suno Na Dilli on Radio City Delhi 91.1In the conversation, we talked about her journey as an influential voice in the radio industry, the current state of the field, and exciting career opportunities. She also shared her tips on becoming a great RJ, embarrassing stories and her SecondAct.Need to start your own podcast? SecondAct Studio is the right place for you. For inquiries, DM us atInstagram: https://www.instagram.com/secondactbyarchhana/LinkedIn: https://bit.ly/3Qz9LmSWebsite: https://thesecondact.in/Follow our Host – Archana DuttaInstagram - https://www.instagram.com/_archanadutta/LinkedIn- https://www.linkedin.com/in/archana-dutta/  Follow Ginnie MahajanInstagram- https://www.instagram.com/rjginnie/Facebook - https://www.facebook.com/rjginnie/#secondact #rjginnie #radiocity #radioshow #sunonadilli #radiojockey #podcastindia

Subscribe to Receive Venkat's Weekly Newsletter Digital SAT is here. Today we feature 2 high school seniors, Eva and Emily from Jenks High School to share their experiences with the Digital SAT. They talk about the structure of the test, how they prepared for it, The differences between the Paper and Digital Test, and their Advice for Juniors. Topics discussed in this episode: Introducing Eva Mahajan, Emily Seo, Jenks High School [] Digital SAT Overall Experience  [] Setup [] Parts of the Test [] Dynamic Modules [] Eva “Prefers Paper” [] Scratch Paper [] Practice Tests [] Differences between the Practice and Real Test [] Paper versus Digital [] Advice for Juniors [] Retaking the Test? [] Our Guests: Eva Mahajan and Emily Seo, Senior Jenks High School, Tulsa OK. Memorable Quote: “So first I would tell them to take as many practice tests as possible, because that's how I like to study. And I soon learned the grammar patterns and the formatting pretty well. And then I would also say, Make sure not to cram study the day or even week before, and to create a schedule over a longer period of time.” Emily Seo. Episode Transcript: Please visit Episode Transcript. Calls-to-action: Follow us on Instagram. To Ask the Guest a question, or to comment on this episode, email podcast@almamatters.io. Subscribe or Follow our podcasts at any of these locations: Apple Podcasts, Spotify and others.

Mona Mahajan, senior investment strategist at Edward Jones, says the stock market is likely to moderate, but investors should lean into any volatility or price declines as an opportunity to buy and build their portfolio. In a wide-ranging Big Interview, Mahajan — who sees a soft landing as the most likely economic outlook — gives her take on every asset class from the Magnificent Seven to small-cap stocks, from bonds and precious metals to alternative investments. Todd Rosenbluth, head of research at VettaFi, makes the Van Eck Morningstar SMID Moat fund his ETF of the Week.  In the Market Call, Jeffrey DeMaso, editor of The Independent Vanguard Adviser, discusses Vanguard funds and ETFs. 

Osteosarcoma Webinar Series: Osteosarcoma Webinar Series: One of our MIB Agents OutSmarting Osteosarcoma 2024 grant recipients, Dr. Shahana Mahajan, a Professor and Principal Investigator from Hunter College of the City University of New York will provide an overview of her funded work on repurposing drugs for metastatic osteosarcoma. Dr. Mahajan will share the recent findings from her lab on testing the efficacy of Riluzole in osteosarcoma cell lines and patient-derived cell lines. Riluzole is a glutamate-release inhibitor and has been used for Amyotrophic Lateral Sclerosis (ALS) for decades and is being tested for other neurodegenerative disorders. Riluzole has shown promising results in glutamate receptor-expressing melanoma and other cancer types. The Mahajan Lab efforts are invested in establishing Riluzole as a possible treatment option for osteosarcoma for which targeted therapy has not been successful due to lack of oncogenic driver mutations. In their lab, Riluzole has shown efficacy in inhibiting proliferation, migration, and invasive ability of osteosarcoma cells in 11 cell lines and 4 patient-derived lines. Dr. Mahajan earned a Ph.D. from the Indian Institute of Science, a premier Institute in India in the field of Molecular Biology. She did postdoctoral studies at Weill Cornell Medical College in the Department of Pharmacology and at NYU Langone Medical Center in the Department of Biochemistry. She continued her research at NYU Langone Medical Center as a Research Assistant Professor until she joined Hunter College as an Assistant Professor in 2007. At Hunter, she continued her research neuroscience to investigate glutamate-induced excitotoxicity in rat hippocampal neurons. After her lab was lost to Hurricane Sandy, she reinitiated her research in osteosarcoma. In 2015, her lab moved to Belfer Research Building which is a part of Weill Cornell Medical College. She was appointed as an adjunct faculty at Weill Cornell Medical College. After a short presentation on this research, she will take questions from attendees. Share your questions in advance with us at Christina@MIBAgents.org.

Mumbai-based director Subhadra Mahajan discusses her debut feature film ‘Second Chance' which just had its Hollywood premiere at AFI, following a World premiere at Karlovy Vary earlier this year. Past inspirations include her love for the Iranian New Wave and Andrea Arnold's ‘Fish Tank'.She speaks on her filmmaking journey, influenced by classic Hollywood films, and reflects on her storytelling process, character development, and the collaborative nature of filmmaking. The discussion also delves into the themes of healing, nature, and the unlikely friendships made while making films. Subhadra emphasizes the importance of breaking traditional filmmaking rules to foster creativity, the challenges of working with a low budget, and the significance of community in film festivals. What Movies Are You Watching?Like, subscribe and follow us on our socials @pastpresentfeature

I am a multi-passionate person- I like writing, my social media work and obviously podcasting. Some people might say that I have a problem with decision making in terms of my career but why do I have to be just one thing? I like doing different things and I have the opportunity so I keep trying. This episode's guest is also like that- she is a doctor and a painter. Dr. Sushma Mahajan has been working as the Head of Radiology at Bhagwan Mahavir Cancer Hospital in Jaipur. During the Covid-19 pandemic, she found her calling as a watercolour artist. Sushma is a natural talent who discovered her passion for art during the lockdown and has become a commercial success.Over the years, Dr. Sushma Mahajan has honed her craft and has held a number of successful exhibitions. Her eclectic artworks adorn the prestigious households of renowned people like Princess Diya Kumari of Jaipur and several suites at the Taj Hotels.Dr. Sushma will share her journey as a doctor and a painter. We talk about the importance of family' support and how as women we need to hold our own and do things that make us happy. You are going to love this one so please send this episode right now to a friend, whatsapp the link and don't forget to rate Little Fixes on your podcast app.Connect with Dr. Sushma Mahajan- https://www.instagram.com/artistsushmamahajan/Shownotes- Use my special link https://zencastr.com/?via=maitri to save 30% off your first month of any Zencastr paid plan.Support the Podcast- https://www.buymeacoffee.com/maitrivermaConnect with @littlefixespodcast on Instagram https://www.instagram.com/littlefixespodcast/ Email me- littlefixespodcast@gmail.comDisclaimer- This podcast is only for educational and entertainment purposes. It doesn't intend to replace the guidance of trained professionals like doctors, psychiatrists, psychologists and coaches etc.Music Credit- Epidemic Sound

She holds numerous world records. But even today, her passion is not really considered 'sport'. It has been over a decade since she was honoured with the Padma Shri. Yet she still has to go struggle for being acknowledged by - and seek permissions from - various authorities. Despite all this, nobody has been able to deter Sheetal Mahajan from her goal. Having overcome, various challenges and hurdles over the past two decades, Sheetal Mahajan has made great strides in the field of skydiving. She has indeed emerged as an inspiration for young athletes in the country. On the occasion of Daughter's Day, let's meet the girl who flies high into - and dives from - the sky.अनेक विश्वविक्रम तिच्या नावावर आहेत. पण आजही ती करते ते 'खेळ' म्हणून गृहित धरलं जात नाही. पद्मश्री पुरस्काराने तिला गौरवण्यात आलं, त्यालाही आता दशकभराचा कालावधी लोटला. तरीही अजूनही राजाश्रयासाठी आणि परवानग्यांसाठी तिला उंबरे झिजवावे लागतात. असं सगळं असलं तरी शीतल महाजनला तिच्या ध्येयापासून कोणीही परावृत्त करू शकलेलं नाही. गेली दोन दशकं विविध आव्हानं आणि अडथळ्यांवर मात करत स्कायडायव्हिंग क्षेत्रात तिने उत्तुंग भरारी घेतली आहे. स्कायडायव्हिंग क्षेत्रातली ही 'शीतल' फुंकर देशातल्या असंख्य युवा खेळाडूंसाठी प्रेरणास्थान ठरली आहे. डॉटर्स डे च्या निमित्ताने भेटूया आकाशाशी नाते जोडणाऱ्या लेकीला.

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Generative ML in chemistry is bottlenecked by synthesis, published by Abhishaike Mahajan on September 18, 2024 on LessWrong. Introduction Every single time I design a protein - using ML or otherwise - I am confident that it is capable of being manufactured. I simply reach out to Twist Biosciences, have them create a plasmid that encodes for the amino acids that make up my proteins, push that plasmid into a cell, and the cell will pump out the protein I created. Maybe the cell cannot efficiently create the protein. Maybe the protein sucks. Maybe it will fold in weird ways, isn't thermostable, or has some other undesirable characteristic. But the way the protein is created is simple, close-ended, cheap, and almost always possible to do. The same is not true of the rest of chemistry. For now, let's focus purely on small molecules, but this thesis applies even more-so across all of chemistry. Of the 1060 small molecules that are theorized to exist, most are likely extremely challenging to create. Cellular machinery to create arbitrary small molecules doesn't exist like it does for proteins, which are limited by the 20 amino-acid alphabet. While it is fully within the grasp of a team to create millions of de novo proteins, the same is not true for de novo molecules in general (de novo means 'designed from scratch'). Each chemical, for the most part, must go through its custom design process. Because of this gap in 'ability-to-scale' for all of non-protein chemistry, generative models in chemistry are fundamentally bottlenecked by synthesis. This essay will discuss this more in-depth, starting from the ground up of the basics behind small molecules, why synthesis is hard, how the 'hardness' applies to ML, and two potential fixes. As is usually the case in my Argument posts, I'll also offer a steelman to this whole essay. To be clear, this essay will not present a fundamentally new idea. If anything, it's such an obvious point that I'd imagine nothing I'll write here will be new or interesting to people in the field. But I still think it's worth sketching out the argument for those who aren't familiar with it. What is a small molecule anyway? Typically organic compounds with a molecular weight under 900 daltons. While proteins are simply long chains composed of one-of-20 amino acids, small molecules display a higher degree of complexity. Unlike amino acids, which are limited to carbon, hydrogen, nitrogen, and oxygen, small molecules incorporate a much wider range of elements from across the periodic table. Fluorine, phosphorus, bromine, iodine, boron, chlorine, and sulfur have all found their way into FDA-approved drugs. This elemental variety gives small molecules more chemical flexibility but also makes their design and synthesis more complex. Again, while proteins benefit from a universal 'protein synthesizer' in the form of a ribosome, there is no such parallel amongst small molecules! People are certainly trying to make one, but there seems to be little progress. So, how is synthesis done in practice? For now, every atom, bond, and element of a small molecule must be carefully orchestrated through a grossly complicated, trial-and-error reaction process which often has dozens of separate steps. The whole process usually also requires non-chemical parameters, such as adjusting the pH, temperature, and pressure of the surrounding medium in which the intermediate steps are done. And, finally, the process must also be efficient; the synthesis processes must not only achieve the final desired end-product, but must also do so in a way that minimizes cost, time, and required sources. How hard is that to do? Historically, very hard. Consider erythromycin A, a common antibiotic. Erythromycin was isolated in 1949, a natural metabolic byproduct of Streptomyces erythreus, a soil mi...

Bianca Blake and Prashant Mahajan are the co-founders of Klickrr.Klickrr is a cloud-based communications platform that provides an easy-to-use, ‘done for you' service, helping businesses send compliant text messages that cut through the clutter and connect with their customers. It is designed to help startups and mid-sized businesses enhance their revenue, make it predictable, and scale efficiently.Bianca, who now holds the role of CEO, is a hugely experienced marketer with a rich professional background, including 15 years of global marketing experience in various sectors including pharmaceutical, consumer healthcare, and FMCG.Prashant, who now acts as Klickrr's CTO, designed and built the Klickrr platform from the ground up, serving over 100 businesses, government agencies, non-profits, and SMEs, sending millions of SMS messages since its inception.In this episode:Bianca and Prashant share their professional and entrepreneurial journey as co-founders of Klickrr.They discuss the key role that SMS can still play in the successful marketing and communications strategy of businesses of all sizes.They offer tips on how a business can set themselves up for success in advance of launching their own SMS marketing channel.Both talk about the own challenges behind the brand development and marketing of the Kilckrr business itself and their plans for future growth as business leaders.

When I learned about today's guest as a working mom, business owner, and CEO of the Nonprofit Science Institute, I couldn't wait to have her on the podcast.Sheela Mahajan helps nonprofits go from intangible and ambiguous goals to quantifiable, measured impact. She is leading the effort in bringing scientific thinking to the nonprofit field. Sheela is sharing her Signals Framework with us, a process to help nonprofits make informed decisions, and explaining how scientific thinking can help your nonprofit.In this episode:[05:58] Practical strategies for science based decision making[11:11] A case study of scientific thinking leading to significant measurable outcomes[18:52] Developing effective implementation plans grounded in evidence[24:36] Coaching clients on scientific data-driven decision making[28:31] Prioritizing buy-in and belonging with the Signals FrameworkRESOURCESTake the leap into successful fundraising with the Savvy Fundraiser Fundamentals Course. The ultimate guide designed for nonprofits that have been around for a while, but haven't delved into the world of fundraising yet. This course covers everything from crafting compelling campaigns to collaborating effectively with your team, ensuring you have all the tools you need to elevate your fundraising efforts.CONNECT WITH SHEELALinkedIn: Sheela MahajanWebsite: nonprofit-science.comIn 2012, I started a nonprofit in a small village in Malawi, living alone, facing many challenges, I built a successful organization. This book is a tale of resilience, passion, and community strength. Discover the highs, lows, lessons learned, and unforgettable moments that shaped my journey. Whether you're in the nonprofit world, thinking of starting one, or just love a great story, pre-order HERE< As the fundraising engine of choice for over 80,000 organizations in 90+ countries, Donorbox's easy-to-use fundraising tools help you raise more money in more ways. Seamlessly embed a customizable donation form into your website that reduces donor drop-off with a 4x faster checkout, launch a crowdfunding or peer-to-peer campaign, sell event tickets, raise funds on the go with Donorbox Live™ Kiosk, and much more. Learn more at donorbox.orgCONNECT WITH HALEYHaley is a Certified Fund Raising Executive (CFRE), Certified Stress Management Coach, and Certified EmC train the trainer. She is the Founder of The Savvy Fundraiser, a nonprofit consulting and coaching business. She has worked in both small and large nonprofit teams in the human services, homelessness, and youth sectors; and she specializes in the EmC process, nonprofit leadership, board development, and fundraising. Haley is a passionate, impact-driven, experienced nonprofit professional whose mission is to empower, elevate and engage nonprofit leaders to build healthy, thriving organizations.Instagram: @thesavvyfundraiser LinkedIn: Haley Cooper, CFREWebsite: thesavvyfundraiser.comProduced by Ideablossoms

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Things I learned talking to the new breed of scientific institution, published by Abhishaike Mahajan on August 30, 2024 on LessWrong. Note: this article is sponsored by and cross-posted to the Good Science Project. They also write a fair bit, and their articles were essential reading for writing this essay! Also, this article would not be possible without the hours of discussion/editing help I've had with several people from these institutions, and a few outside of them. Huge shout-out to all of them! Introduction Arcadia Science, Speculative Technologies, FutureHouse, Arc, and Convergent. All of these are a new form of scientific institute. Most are funded entirely by a few billionaires. Most are non-profits. Most of them focus on the life-sciences. Most of them have sprung up in just the last few years. They do all also have one common thread: a grand statement. We are an experiment in a new way to do science. And they are! Traditionally, research is conducted in academic or private industry labs - dependent on NIH grants in the former and markets in the latter. Given the (often singular) sources of no-strings-attached funding, these new institutions need not satisfy either the NIH or the markets, allowing them to conduct research in a unique fashion. In one sense, the experimental aspect of these institutions revolves around the focus of the research itself, addressing fields or using methods that the founders - correctly or not - view as underserved/underutilized. But, on a more subtle level, the experimental aspect could be more closely tied to the culture of these organizations. Institutions like Arcadia, FutureHouse, and the rest could be viewed as the production of auteurs - a term from filmmaking for films with such a heavy sense of the director's personal taste that the film is inseparable from the director. This is where the novelty within these institutions primarily lie, in how the founders of the institute wish science was conducted. And wielding billions of dollars, thousands of hours of work, and hundreds of scientists as a means to test whether their theories are correct. Of course, nothing under the sun is truly new. There is an age-old history of scientist dissatisfaction with how 'things are traditionally done', and confidently building new institutions to solve the problems they've seen. Many of these are now household names amongst researchers: Broad Institute, Whitehead Institute, Max Planck Society, Howard Hughes Medical Institute (HHMI), and so on. Each of these were started with similar contrarian mentalities as the current era of institutions. Some of these were more experimental than others, most notably HHMI, which prized itself on its focus on interdisciplinary research above all else. But all were experiments, many of them extraordinarily successful. Yet, the current iteration of new research institutes is still arguably more experimental than its ancestors. While the last generation of institutes was typically tied directly to universities, the current era of ones (outside of Arc) are independent, allowing them a larger sense of opinionation on how science should be done. But, despite this experimentation, there is relatively little information out there on what's going on inside them. Not in terms of science, but more-so the vibes. While aspects of these organizations have been written about previously, such as in articles in The Atlantic and Endpoints, they aren't assessing vibes! These other articles are, first and foremost, news-pieces; valuable, but lack any opinionated observations on the inner-workings of the institutions. Nadia Asparouhova's essay on the subject comes closest to this regarding the history of these institutions, but still few details on how they practically function. This essay attempts to discuss that missing s...

Link to original articleWelcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Things I learned talking to the new breed of scientific institution, published by Abhishaike Mahajan on August 30, 2024 on LessWrong. Note: this article is sponsored by and cross-posted to the Good Science Project. They also write a fair bit, and their articles were essential reading for writing this essay! Also, this article would not be possible without the hours of discussion/editing help I've had with several people from these institutions, and a few outside of them. Huge shout-out to all of them! Introduction Arcadia Science, Speculative Technologies, FutureHouse, Arc, and Convergent. All of these are a new form of scientific institute. Most are funded entirely by a few billionaires. Most are non-profits. Most of them focus on the life-sciences. Most of them have sprung up in just the last few years. They do all also have one common thread: a grand statement. We are an experiment in a new way to do science. And they are! Traditionally, research is conducted in academic or private industry labs - dependent on NIH grants in the former and markets in the latter. Given the (often singular) sources of no-strings-attached funding, these new institutions need not satisfy either the NIH or the markets, allowing them to conduct research in a unique fashion. In one sense, the experimental aspect of these institutions revolves around the focus of the research itself, addressing fields or using methods that the founders - correctly or not - view as underserved/underutilized. But, on a more subtle level, the experimental aspect could be more closely tied to the culture of these organizations. Institutions like Arcadia, FutureHouse, and the rest could be viewed as the production of auteurs - a term from filmmaking for films with such a heavy sense of the director's personal taste that the film is inseparable from the director. This is where the novelty within these institutions primarily lie, in how the founders of the institute wish science was conducted. And wielding billions of dollars, thousands of hours of work, and hundreds of scientists as a means to test whether their theories are correct. Of course, nothing under the sun is truly new. There is an age-old history of scientist dissatisfaction with how 'things are traditionally done', and confidently building new institutions to solve the problems they've seen. Many of these are now household names amongst researchers: Broad Institute, Whitehead Institute, Max Planck Society, Howard Hughes Medical Institute (HHMI), and so on. Each of these were started with similar contrarian mentalities as the current era of institutions. Some of these were more experimental than others, most notably HHMI, which prized itself on its focus on interdisciplinary research above all else. But all were experiments, many of them extraordinarily successful. Yet, the current iteration of new research institutes is still arguably more experimental than its ancestors. While the last generation of institutes was typically tied directly to universities, the current era of ones (outside of Arc) are independent, allowing them a larger sense of opinionation on how science should be done. But, despite this experimentation, there is relatively little information out there on what's going on inside them. Not in terms of science, but more-so the vibes. While aspects of these organizations have been written about previously, such as in articles in The Atlantic and Endpoints, they aren't assessing vibes! These other articles are, first and foremost, news-pieces; valuable, but lack any opinionated observations on the inner-workings of the institutions. Nadia Asparouhova's essay on the subject comes closest to this regarding the history of these institutions, but still few details on how they practically function. This essay attempts to discuss that missing s...

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: A primer on the current state of longevity research, published by Abhishaike Mahajan on August 22, 2024 on LessWrong. Note: This post is co-authored with Stacy Li, a PhD student at Berkeley studying aging biology! Highly appreciate all her help in writing, editing, and fact-checking my understanding! Introduction The last time I read about aging research deeply was around 2021. The general impression I was getting was that aging research was increasingly more and more funded (good!). Unfortunately, none of the money led to actionable or useful insights (bad). Over time, you get slightly burnt out by all the negative news. After getting a job in biotech, I kept a hazy eye on the subject but mostly tuned out of it entirely. But, especially today, I am curious: how has the aging field progressed in the last few years? Since 2021, what has changed? In this post, I'll share a list of immediate questions about the state of affairs in aging research, and the answers I've found for them. For each question, I'll offer some basic background knowledge required to understand the question. Feel free to skip that part if you already understand the question! Did the therapeutic focus on sirtuins amount to much? Background Sirtuins are a family of signaling proteins, commonly referred to by their corresponding gene name, SIRT1, SIRT2, all the way up to SIRT7. Their primary role is deacetylation, which is just the removal of a chemical marker (acetyl) on proteins. It was noticed in the 1980s that some sirtuin classes were especially involved in three key activities: modifying histones, which are proteins that tune the accessibility of DNA in the nucleus, transcriptional modification, which determines how DNA is interpreted by the body, and DNA repair, which speaks for itself. And anything involved in modifying and maintaining DNA is something worth paying attention to! Studies in the 2000s showed that the activity of specific sirtuin classes strongly correlated with age; the young had more sirtuin activity, and the old had less. This seemed to be causative in aging; overexpressing certain sirtuin genes led to lifespan increase and downregulation of them led to lifespan decrease. The results were a bit mixed, and the results were for yeast cells - always a red flag - but there was some promise in viewing sirtuins as an aging target. It turns out that editing humans to safely overexpress sirtuin genes is somewhat hard to do (as is expressing any gene in humans). But there was an easy way around that: focus on molecules that are required for sirtuin to do its job. A class of therapeutics grew from this: sirtuin-activating compounds. How do you activate sirtuins? Well, sirtuins are dependent on NAD+, or nicotinamide adenine dinucleotide, to perform their primary function. Increasing cellular NAD+ levels could also be a way to indirectly push for more sirtuin activity. Practically speaking, NAD+ bioavailability is poor, so supplementation with precursors to NAD+, such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), was instead used. There are plenty of other compounds in this category too: resveratrol, fisetin, and quercetin are all names you may hear mentioned. How has this fared? Answer TLDR: The whole sirtuin theory was losing steam by the time I started reading about it a few years ago. It's only gotten worse. Nothing particularly useful has come from sirtuin-focused therapies, and likely nothing ever will. A Cell paper from 2018 found that NAD+ precursor supplementation didn't improve mice longevity. To be fair, they did show that supplementation improves some aspects of health-span, specifically improved glucose metabolism and reduced oxidative stress to the liver in aged mice, so still potentially useful. But nothing revolutionary. Still, human clinical trials ...

Link to original articleWelcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: A primer on the current state of longevity research, published by Abhishaike Mahajan on August 22, 2024 on LessWrong. Note: This post is co-authored with Stacy Li, a PhD student at Berkeley studying aging biology! Highly appreciate all her help in writing, editing, and fact-checking my understanding! Introduction The last time I read about aging research deeply was around 2021. The general impression I was getting was that aging research was increasingly more and more funded (good!). Unfortunately, none of the money led to actionable or useful insights (bad). Over time, you get slightly burnt out by all the negative news. After getting a job in biotech, I kept a hazy eye on the subject but mostly tuned out of it entirely. But, especially today, I am curious: how has the aging field progressed in the last few years? Since 2021, what has changed? In this post, I'll share a list of immediate questions about the state of affairs in aging research, and the answers I've found for them. For each question, I'll offer some basic background knowledge required to understand the question. Feel free to skip that part if you already understand the question! Did the therapeutic focus on sirtuins amount to much? Background Sirtuins are a family of signaling proteins, commonly referred to by their corresponding gene name, SIRT1, SIRT2, all the way up to SIRT7. Their primary role is deacetylation, which is just the removal of a chemical marker (acetyl) on proteins. It was noticed in the 1980s that some sirtuin classes were especially involved in three key activities: modifying histones, which are proteins that tune the accessibility of DNA in the nucleus, transcriptional modification, which determines how DNA is interpreted by the body, and DNA repair, which speaks for itself. And anything involved in modifying and maintaining DNA is something worth paying attention to! Studies in the 2000s showed that the activity of specific sirtuin classes strongly correlated with age; the young had more sirtuin activity, and the old had less. This seemed to be causative in aging; overexpressing certain sirtuin genes led to lifespan increase and downregulation of them led to lifespan decrease. The results were a bit mixed, and the results were for yeast cells - always a red flag - but there was some promise in viewing sirtuins as an aging target. It turns out that editing humans to safely overexpress sirtuin genes is somewhat hard to do (as is expressing any gene in humans). But there was an easy way around that: focus on molecules that are required for sirtuin to do its job. A class of therapeutics grew from this: sirtuin-activating compounds. How do you activate sirtuins? Well, sirtuins are dependent on NAD+, or nicotinamide adenine dinucleotide, to perform their primary function. Increasing cellular NAD+ levels could also be a way to indirectly push for more sirtuin activity. Practically speaking, NAD+ bioavailability is poor, so supplementation with precursors to NAD+, such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), was instead used. There are plenty of other compounds in this category too: resveratrol, fisetin, and quercetin are all names you may hear mentioned. How has this fared? Answer TLDR: The whole sirtuin theory was losing steam by the time I started reading about it a few years ago. It's only gotten worse. Nothing particularly useful has come from sirtuin-focused therapies, and likely nothing ever will. A Cell paper from 2018 found that NAD+ precursor supplementation didn't improve mice longevity. To be fair, they did show that supplementation improves some aspects of health-span, specifically improved glucose metabolism and reduced oxidative stress to the liver in aged mice, so still potentially useful. But nothing revolutionary. Still, human clinical trials ...

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: A primer on why computational predictive toxicology is hard, published by Abhishaike Mahajan on August 19, 2024 on LessWrong. Introduction There are now (claimed) foundation models for protein sequences, DNA sequences, RNA sequences, molecules, scRNA-seq, chromatin accessibility, pathology slides, medical images, electronic health records, and clinical free-text. It's a dizzying rate of progress. But there's a few problems in biology that, interestingly enough, have evaded a similar level of ML progress, despite there seemingly being all the necessary conditions to achieve it. Toxicology is one of those problems. This isn't a new insight, it was called out in one of Derek Lowe's posts, where he said: There are no existing AI/ML systems that mitigate clinical failure risks due to target choice or toxicology. He also repeats it in a more recent post: '…the most badly needed improvements in drug discovery are in the exact areas that are most resistant to AI and machine learning techniques. By which I mean target selection and predictive toxicology.' Pat Walters also goes into the subject with much more depth, emphasizing how difficult the whole field is. As someone who isn't familiar at all with the area of predictive toxicology, that immediately felt strange. Why such little progress? It can't be that hard, right? Unlike drug development, where you're trying to precisely hit some key molecular mechanism, assessing toxicity almost feels…brutish in nature. Something that's as clear as day, easy to spot out with eyes, easier still to do with a computer trained to look for it. Of course, there will be some stragglers that leak through this filtering, but it should be minimal. Obviously a hard problem in its own right, but why isn't it close to being solved? What's up with this field? Some background One may naturally assume that there is a well-established definition of toxicity, a standard blanket definition to delineate between things that are and aren't toxic. While there are terms such as LD50, LC50, EC50, and IC50, used to explain the degree by which something is toxic, they are an immense oversimplification. When we say a substance is "toxic," there's usually a lot of follow-up questions. Is it toxic at any dose? Only above a certain threshold? Is it toxic for everyone, or just for certain susceptible individuals (as we'll discuss later)? The relationship between dose and toxicity is not always linear, and can vary depending on the route of exposure, the duration of exposure, and individual susceptibility factors. A dose that causes no adverse effects when consumed orally might be highly toxic if inhaled or injected. And a dose that is well-tolerated with acute exposure might cause serious harm over longer periods of chronic exposure. The very definition of an "adverse effect" resulting from toxicity is not always clear-cut either. Some drug side effects, like mild nausea or headache, might be considered acceptable trade-offs for therapeutic benefit. But others, like liver failure or birth defects, would be considered unacceptable at any dose. This is particularly true when it comes to environmental chemicals, where the effects may be subtler and the exposure levels more variable. Is a chemical that causes a small decrease in IQ scores toxic? What about one that slightly increases the risk of cancer over a lifetime (20+ years)? And this is one of the major problems with applying predicting toxicology at all - defining what is and isn't toxic is hard! One may assume the FDA has clear stances on all these, but even they approach it on a 'vibe-based' perspective. They simply collate the data from in-vitro studies, animal studies, and human clinical trials, and arrive to an approval/no-approval conclusion that is, very often, at odds with some portion of the medical comm...

Link to original articleWelcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: A primer on why computational predictive toxicology is hard, published by Abhishaike Mahajan on August 19, 2024 on LessWrong. Introduction There are now (claimed) foundation models for protein sequences, DNA sequences, RNA sequences, molecules, scRNA-seq, chromatin accessibility, pathology slides, medical images, electronic health records, and clinical free-text. It's a dizzying rate of progress. But there's a few problems in biology that, interestingly enough, have evaded a similar level of ML progress, despite there seemingly being all the necessary conditions to achieve it. Toxicology is one of those problems. This isn't a new insight, it was called out in one of Derek Lowe's posts, where he said: There are no existing AI/ML systems that mitigate clinical failure risks due to target choice or toxicology. He also repeats it in a more recent post: '…the most badly needed improvements in drug discovery are in the exact areas that are most resistant to AI and machine learning techniques. By which I mean target selection and predictive toxicology.' Pat Walters also goes into the subject with much more depth, emphasizing how difficult the whole field is. As someone who isn't familiar at all with the area of predictive toxicology, that immediately felt strange. Why such little progress? It can't be that hard, right? Unlike drug development, where you're trying to precisely hit some key molecular mechanism, assessing toxicity almost feels…brutish in nature. Something that's as clear as day, easy to spot out with eyes, easier still to do with a computer trained to look for it. Of course, there will be some stragglers that leak through this filtering, but it should be minimal. Obviously a hard problem in its own right, but why isn't it close to being solved? What's up with this field? Some background One may naturally assume that there is a well-established definition of toxicity, a standard blanket definition to delineate between things that are and aren't toxic. While there are terms such as LD50, LC50, EC50, and IC50, used to explain the degree by which something is toxic, they are an immense oversimplification. When we say a substance is "toxic," there's usually a lot of follow-up questions. Is it toxic at any dose? Only above a certain threshold? Is it toxic for everyone, or just for certain susceptible individuals (as we'll discuss later)? The relationship between dose and toxicity is not always linear, and can vary depending on the route of exposure, the duration of exposure, and individual susceptibility factors. A dose that causes no adverse effects when consumed orally might be highly toxic if inhaled or injected. And a dose that is well-tolerated with acute exposure might cause serious harm over longer periods of chronic exposure. The very definition of an "adverse effect" resulting from toxicity is not always clear-cut either. Some drug side effects, like mild nausea or headache, might be considered acceptable trade-offs for therapeutic benefit. But others, like liver failure or birth defects, would be considered unacceptable at any dose. This is particularly true when it comes to environmental chemicals, where the effects may be subtler and the exposure levels more variable. Is a chemical that causes a small decrease in IQ scores toxic? What about one that slightly increases the risk of cancer over a lifetime (20+ years)? And this is one of the major problems with applying predicting toxicology at all - defining what is and isn't toxic is hard! One may assume the FDA has clear stances on all these, but even they approach it on a 'vibe-based' perspective. They simply collate the data from in-vitro studies, animal studies, and human clinical trials, and arrive to an approval/no-approval conclusion that is, very often, at odds with some portion of the medical comm...

Elon Musk Says Dubai Is A Beautiful City! An Employee Praised Her Former Emirati Boss Who Showed Her Compassion During A Personal CrisisA Dubai Tourist Is So Impressed With Taxi Drivers That He Would Just Come Back For ThemA Tourist From Morocco Was Invited To A Stranger's Home In The Burj KhalifaReema Mahajan Who Helped Building a Vibrant Community of 100,000 Indian Women in the UAE

Reema Mahajan Who Helped Building a Vibrant Community of 100,000 Indian Women in the UAE

In this episode, Daniel Arnold sits down with Dr. Vidur Mahajan   Dr. Vidur Mahajan is the Chief Executive Officer of CARPL.ai, the world's first end-to-end platform for testing, deployment, and monitoring of medical imaging AI solutions. With a background as a physician and an MBA from the Wharton School of Business, he has significantly contributed to healthcare technology adoption.   They discuss the company's two-step AI deployment framework (Dev-D), which helps institutions discover, test, and integrate AI applications. Key clients include academic centers like Mass General and Yale, and the Singapore government, using the platform for AI benchmarking and deployment.   The conversation highlights the significant investment radiologists, especially in India, make in upskilling with AI technology. Dr. Mahajan compares the current state of radiology AI to the early days of MRI, noting that while AI's capabilities are proven, its practical usefulness is still being established. They observe new AI companies emerging from regions like Eastern Europe and Southeast Asia.   A critical lesson shared involves the importance of proper client qualification in sales, avoiding pushing products onto uninterested clients. The guest emphasizes the need for a neutral platform to evaluate AI solutions transparently, ensuring healthcare providers can choose the best tools without bias. The episode concludes with insights on the future of radiology AI and reflections on the entrepreneurial journey in this field.   Learn more at https://medality.com/the-radiology-report-podcast   Like this episode? We'd love it if you could leave us a five-star review! And make sure to subscribe, so you never miss an opportunity to hear from the leaders in radiology.

Amitt Mahajan is the Founder of Proof of Play, the creators of Pirate Nation, the fully onchain free-to-play pirate-themed roleplaying game (RPG). Prior to founding Proof of Play, Amitt was the founder and CTO of MyMiniLife (acquired by Zynga), founder and CEO of Toro (acquired by Google), and the co-founder and CTO of Rare Bits, an NFT marketplace launched in 2018 the same week as OpenSea. While at Zynga, he co-created the game FarmVille (300M players, $1B+ in revenue) and served as the CTO of Zynga Japan. Before his entrepreneurial work, Mahajan was an engineer at Epic Games on the Unreal Engine and Gears of War.In this conversation, we discuss:- Building FarmVille and working at Zynga, a top 3 gaming studio of all time- The importance of distribution in gaming- Distribution in FB vs Telegram vs Discord- Social gaming- Creating games = giving multiple choices and giving high player agency- “Finding the fun”- Building decentralized games and gaming infrastructure- Crypto is ethical neutral technology- Importance of streaming in today's games- Building community- Dev cycle speedPirate NationWebsite: piratenation.gameX: @PirateNationDiscord: discord.gg/piratenationAmitt MahajanX: @amittmLinkedIn: Amitt Mahajan  ---------------------------------------------------------------------------------  This episode is brought to you by PrimeXBT.  PrimeXBT offers a robust trading system for both beginners and professional traders that demand highly reliable market data and performance. Traders of all experience levels can easily design and customize layouts and widgets to best fit their trading style. PrimeXBT is always offering innovative products and professional trading conditions to all customers.   PrimeXBT is running an exclusive promotion for listeners of the podcast. After making your first deposit, 50% of that first deposit will be credited to your account as a bonus that can be used as additional collateral to open positions.  Code: CRYPTONEWS50  This promotion is available for a month after activation. Click the link below:  PrimeXBT x CRYPTONEWS50

Join us on Cyrus Says for an illuminating conversation with Shruti Mahajan, the visionary casting director behind Sanjay Leela Bhansali's "Heeramandi"! She also talks about her MBA days, shifting from Jaipur to Mumbai.Get exclusive insights into the casting process of "Heeramandi" and learn how Shruti is reshaping Indian cinema's global image. From her unique approach to finding fresh faces to her dreams of putting Indian talent on the world stage, Shruti reveals it all.Don't miss this fascinating deep dive into the art of casting and the future of Indian cinema with one of the industry's most influential behind-the-scenes players!#Heeramandi #Cyrus Says #SanjayLeelaBhansaliSee omnystudio.com/listener for privacy information.

In "Second Chance", world-premiering in the Proxima Competition of the Karlovy Vary IFF, "The journey of Nia is one of finding light at the end of a very long and dark tunnel." The post “Second Chance”, an interview with director Subhadra Mahajan and actress Dheera Johnson appeared first on Fred Film Radio.

Shruti Mahajan Deorah is the Director at India Energy & Climate Center (IECC) at UC Berkeley's Goldman School of Public Policy - leveraging clean energy technology and policy expertise to catalyze rapid transformation of energy systems in close collaboration with Indian policymakers and business leaders. She is an alum of UC Berkeley and IIT Bombay. --- Support this podcast: https://podcasters.spotify.com/pod/show/theindustryshow/support

 Vietnam's tourism industry is making positive strides, but are the current resources enough for it to reach the heights of Thailand's tourism?

Embark on a journey toward holistic wellness as we delve into the realm of functional nutrition with Kajal Mahajan, a leading expert in the field. In this episode, we explore the transformative power of nutrition beyond conventional approaches. Join us as we uncover the wisdom behind functional nutrition and its profound impact on overall well-being. [00:32] - About Kajal Mahajan Kajal is the Founder and Head Coach of The Positive Practice. She holds a Master's in Clinical Nutrition with an undergraduate degree in Sports Science and Health Psychology. --- Support this podcast: https://podcasters.spotify.com/pod/show/tbcy/support

Nitin Mahajan, a visionary in the tech industry, is actively transforming the tech universe one company at a time while currently building 88 Ventures to achieve unprecedented success. Recognizing the transformative power of AI, Nitin is passionate about ensuring its widespread adoption in a way that positively impacts lives and maximizes its reach to the masses. 88 Ventures serves as the culmination of Nitin's unwavering dedication, extensive knowledge, and far-reaching vision. Through this venture, he envisions unlocking new opportunities and fostering meaningful connections in the professional world by embracing the potential of technology. In addition to his role at 88 Ventures, Nitin has also embraced the role of an Angel Investor, supporting individuals with grand ambitions and empowering them to bring their unique visions to life. His mission is to uplift those whose aspirations may go unnoticed by others. If you share Nitin's values and are driven to build profitable bootstrap businesses while making a positive impact, he is here to guide you on your journey. Reach out to Nitin, and rest assured that you will connect with someone who understands your vision and is committed to helping you succeed. Just drop him a text, and a world of possibilities awaits! LinkedIn: https://www.linkedin.com/in/nitinmahajan2/ Website: https://88ventures.org/ --- Support this podcast: https://podcasters.spotify.com/pod/show/geeksofthevalley/support

Global Product Management Talk is pleased to bring you the next episode of... Product Mastery Now with host Chad McAllister, PhD. The podcast is all about helping people involved in innovation and managing products become more successful, grow their careers, and STANDOUT from their peers. About the Episode:  Today we are talking about aspects of the Market Research knowledge area for product mastery. Specifically, we are discussing how to overcome challenges collecting actionable customer insights. Helping us with this is Prashant Mahajan, the founder of  Zeda.io. Prashant is an experienced product manager and leader, having guided product development in several organizations. In these experiences, he identified a critical gap: Many Product Managers are unsure if they are building the right products because they can't access customer feedback, customer insight, or sentiment. This led him to developing Zeda.io, which is also focused on the importance of publicly sharing product roadmaps and progress with customers.

In this episode, we discuss Pakistani politics, Oct. 7th attack & the Israel-Hamas war, and some more impersonations by Sonam!

In this episode, we discuss the Pakistani and Indian YouTube scene, the blasphemy incident in Lahore and Pakistani journalism scene. Oh, and Sonam does some famous impersonations for us!

Chandan Mahajan is the co-founder of dotkonnekt - helping brands grow their business organically by combining the power of commerce, community, and content. dotkonnekt is partnering with progressive marketers on creating a new growth playbook, moving beyond ineffective paid ads and expensive custom development. Previously Chandan held senior leadership positions with Sutherland and Wipro. --- Support this podcast: https://podcasters.spotify.com/pod/show/theindustryshow/support

  Network configuration analysis has always been the domain of commercial-grade software. Batfish changes all that with an open source, community-supported tool that can find errors and guarantees the correctness of planned or current network configurations. Ratul Mahajan joins Tom Ammon and Russ White to talk about this new tool, its capabilities, and the importance of network configuration analysis.

You may recognize him from the first episode in our "Lab of the Future" series: Rishi Mahajan, M.S., lead automation engineer at Regeneron, returns to the podcast to share his career story! Rishi shares his unconventional journey, from childhood with no clear career aspirations to becoming a seasoned automation engineer. He highlights his college major selection and how he navigated education challenges in India before pursuing his master's in biotechnology in the United States.He later entered the world of lab research during his master's program, emphasizing the importance of internships and networking. He discusses the hurdles he faced, the role of networking in securing his internship at Regeneron, and the subsequent transition to a full-time position. Enjoy this advice-filled conversation addressing the power of networking, with Rishi providing practical tips for individuals, even introverts, to build meaningful connections. He emphasizes the casual nature of networking, the importance of genuine conversations and dispels the fear of making mistakes when reaching out to seasoned professionals.Full Transcript Available on BuzzsproutOur Sponsor for this EpisodeBenchling creates the software that powers the biotechnology industry. More than 200,000 scientists at over 1,200 companies globally —  from cutting-edge start-ups to 20+ of the 50 largest global biopharma — rely on the Benchling R&D Cloud as their central source of truth for scientific data, analysis, and collaboration. Benchling is on a mission to accelerate scientific progress through advanced software that's purpose-built for biology.To learn more,  visit: Benchling.comStay connected with SLASOnline at www.slas.orgFacebookTwitter @SLAS_OrgLinkedInInstagram @slas_orgYouTubeAbout SLASSLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building. Upcoming SLAS Events: SLAS Building Biology in 3D Symposium April 16-17, 2024 Jupiter, FL, USA SLAS Europe 2024 Conference and Exhibition May 27-29, 2024 Barcelona, Spain View the full events calendar

The pharmaceutical behemoth, Walgreens Boots Alliance, Inc. (WBA) recently shared their latest earnings report. The company's CFO, Manmohan Mahajan, during his dialogue with the investors, mentioned the influences of the changing market paradigm. Acknowledging the challenges posed by consumer pressures from inflation, decreased savings, and slower-than-expected market trends in pharmacy script volumes, he said, "We are navigating the accumulating consumer pressures from inflation and depleted savings and somewhat slower-than-anticipated market trends in pharmacy script volumes, including impacts from a weaker respiratory season and Medicaid redetermination." Although the CEO accepted the broad challenges these shifts pose on the company functions, he remained hopeful about the company's capacity to navigate through these transitions. Walgreens Boots Alliance has consistently demonstrated strong financial indicators, a testament to the company's portfolio of world-class services and products, and strategic undertakings. This has empowered the company to steadily adapt to the evolving customer preferences and market tendencies. As part of their continuous evolution, the company lays out a strategy for the future, complete with bold plans and investments. The steady financial solidity that WBA displays is not a standalone phenomenon, rather an outcome of a well-thought-out product range and high-quality services. One of the pivotal growth narratives of the company is their unique health services ecosystem. "We can work inside of, and we've proven, we're inside of cost-plus models now. We have a very robust cash program. And we think we're a terrific partner to others that want to win in the marketplace with these more innovative models that they have talked about and that they are pushing into the market" stated Mahajan of WBA's innovative approach. The CEO's words underline the company's readiness to engage in strategic collaborations, thereby buttressing its standing as a crucial collaborator in the market. As the company forges new partnerships with vital healthcare entities, its growth trajectory is set to keep accelerating. For more PSFK research : www.psfk.com  This email has been published and shared for the purpose of business research and is not intended as investment advice.

We're back! We're kicking off a new season of episodes with an interview with Dr. Paul Bloom to discuss his new book Psych. We discuss science communication, the limits and value of psychology, whether researchers should be siloed in academia, the problem with empathy, if kids are little bigots, and if social psychology isn't paying enough attention to policy. Psych: The Story of The Human Mind Paul's webpage (with links to other books), Substack “Small Potatoes” and Twitter Research cited by Kiley Hamlin and Karen Wynn:  Hamlin, J. K., & Wynn, K. (2011). Young infants prefer prosocial to antisocial others. Cognitive development, 26(1), 30-39. Hamlin, J. K., Mahajan, N., Liberman, Z., & Wynn, K. (2013). Not like me = bad: Infants prefer those who harm dissimilar others. Psychological science, 24(4), 589-594.

In this bonus Q&A interview with Deep, she shares:Her proudest moment and biggest failure in her career so farA trend that she is following in Talent Development right nowThe biggest challenge she sees in Talent Development todayBooks that have made a big impact on her lifeOne piece of career advice she has for youDeep Mahajan, Juniper Networks' Vice President of Talent Management, is an accomplished leader dedicated to organizational success through talent capability and culture building. Her extensive background spans diverse industries, holding key roles that showcase her adeptness in navigating complexities across organizations of different sizes and stages, steering teams towards excellence.With an MBA from Symbiosis International University and a BA in Economics from Delhi University, Deep's strategic prowess is bolstered by hands-on experience in leading transformative initiatives that impact the culture and people capabilities in an organization. With over 20+ years of HR expertise, her previous roles include heading People Development and Culture at Nutanix and contributing to VMware's global people development team. Deep's palpable passion for nurturing growth and learning shines within the dynamic tech landscape.Deep's visionary leadership permeates Juniper Networks, fostering a culture of perpetual development. Her continued guidance shapes the company's path, propelling both individuals and the organization towards continuous development and enduring success.Connect with Andy Storch here:WebsiteLinkedInJoin us in the Talent Development Think Tank Community!Connect with Deep Mahajan:LinkedIn

In today's episode, we dive into the world of building an internal talent marketplace with our special guest, Deep Mahajan, VP of Talent Management at Juniper Networks. Deep shares her insights on the challenges and successes of implementing an internal talent marketplace, the importance of embracing change in the workplace, and the power of skills as the new currency for career development. You'll learn:How Juniper Networks defines an internal talent marketplace and the key benefits they have seen from implementing this systemThe importance of a mindset shift among employers and HR professionals in embracing the concept of an internal talent marketplace. Ways in which the pandemic has changed employees' expectations and needs when it comes to career development and talent mobility and how organizations can adapt.How organizations can foster a culture of skill development and empower employees to direct their own development using skills-based orientationDeep Mahajan, Juniper Networks' Vice President of Talent Management, is an accomplished leader dedicated to organizational success through talent capability and culture building. Her extensive background spans diverse industries, holding key roles that showcase her adeptness in navigating complexities across organizations of different sizes and stages, steering teams towards excellence.With an MBA from Symbiosis International University and a BA in Economics from Delhi University, Deep's strategic prowess is bolstered by hands-on experience in leading transformative initiatives that impact the culture and people capabilities in an organization. With over 20+ years of HR expertise, her previous roles include heading People Development and Culture at Nutanix and contributing to VMware's global people development team. Deep's palpable passion for nurturing growth and learning shines within the dynamic tech landscape.Deep's visionary leadership permeates Juniper Networks, fostering a culture of perpetual development. Her continued guidance shapes the company's path, propelling both individuals and the organization towards continuous development and enduring success.Connect with Andy Storch here:WebsiteLinkedInJoin us in the Talent Development Think Tank Community!Connect with Deep Mahajan:LinkedIn

Madhura Mahajan, Head of Department and the Dean of IQAC in the Department of Printing Engineering at PVG's College of Engineering and Technology joins Deborah Corn to discuss the role of print education in nurturing student talents, the challenges of attracting a skilled workforce, and facing the embrace of digital printing in India. Mentioned in This Episode: Madhura Mahajan: https://www.linkedin.com/in/madhuramahajan06/ Ink Stories: https://www.youtube.com/@inkstories3525 ‘Is there a future in printing engineering?' | Madhura Mahajan | Ink Stories Ep - 22: https://youtu.be/axdBly7YbZU Printing Technology — PVG's College of Engineering and Technology and G. K Pat (Wani) Institue of Management: https://www.pvgcoet.ac.in/academics/departments/printing-technology/ Printing Department PVG's COET on Instagram: https://www.instagram.com/printing_department_pvgcoet/ Printing Department PVG's COET on YouTube: https://youtube.com/@departmentofprintingengine3625 Deborah Corn: https://www.linkedin.com/in/deborahcorn/  Print Media Centr: https://printmediacentr.com Project Peacock: https://ProjectPeacock.TV Girls Who Print: https://girlswhoprint.net Print Across America: https://printacrossamerica.com/

Karan Mahajan reads his story “The True Margaret,” which appears in the August 14, 2023, issue of the magazine. Mahajan is the author of two novels, “Family Planning” and “The Association of Small Bombs,” which won the New York Public Library Young Lions Fiction Award in 2017.

Have you already been at your desk an hour before everyone else shows up in the morning (and don't complain about working long hours)?Do you hate wasting time and find yourself getting impatient during meetings, asking to "get to the bottom line?"Do you find it difficult to unplug from work, even on vacation or after a health scare?Is it difficult to stay engaged if the goals are clearly outlined?If these resonate, you might be an Enneagram Three...Listen in to this live interview with Type 3 "informant," Jayshree Mahajan, to learn more about the Enneagram 3 energy whether you're trying to narrow down your dominant type or looking to better understand a Type 3 in your life.Connect with Jayshree and let her know what resonates with you most about what she shared! https://www.linkedin.com/in/jayshree-mahajan/If you'd like to catch the full video interview, you'll find it on YouTube here:https://youtu.be/uwfB2RN2UY4******

Veera Mahajan is an author, coach, mediator, and speaker. Co-managed a technology company that had a $100M+ exit. She has held various leadership positions in the corporate world, launched and ran the Malibu Chronicle magazine that was acquired by Malibu Times. Veera is an alum of Pepperdine Law and has a Master's in Spiritual Psychology and Mediation and Dispute Resolution. She helps raise funds for various non-profit causes. She is a TedX speaker and deeply passionate about helping women. --- Support this podcast: https://podcasters.spotify.com/pod/show/theindustryshow/support

Dr Marlena Wosiski-Kuhn recaps a recent journal club covering the paper by Mahajan and colleagues: Serious Bacterial Infections in Young Febrile Infants with Positive Urinalysis Results.

In this episode, Michael speaks with with Shauna Mahajan, lead social scientist with the global science team of the World Wildlife Fund, or WWF.  During their conversation, Shauna shares her thoughts about her educational experiences and her time at WWF, during which she has focused on helping conservation projects become more inclusive and holistic. Shauna has done this in part by developing decision support tools, including a tool called Elinor, so named in honor of Elinor Ostrom. This tool helps researchers and practitioners, in the language of the Elinor website, “track attributes critical to the success of area-based conservation over time, and share this information with decision makers and conservation supporters”.  Shauna also discusses her experiences on the ground to support inclusive and holistic conservation, and a new program at WWF that is encouraging the career development of underrepresented groups at the organization.   Shauna's website: https://www.worldwildlife.org/experts/shauna-mahajan References Deveson, A. (2005). Resilience (First Edition). Roundhouse Publishing Group. Mahajan, S. L., Estradivari, E., Ojwang, L., & Ahmadia, G. N. (2022). The good, the bad, and the ugly: reflections on co-designing science for impact between the Global South and Global North. ICES Journal of Marine Science: Journal Du Conseil. https://doi.org/10.1093/icesjms/fsac115 Mahajan, S. L., Glew, L., Rieder, E., Ahmadia, G., Darling, E., Fox, H. E., Mascia, M. B., & McKinnon, M. (2019). Systems thinking for planning and evaluating conservation interventions. Conservation Science and Practice, 1(7), e44. https://doi.org/10.1111/csp2.44 https://elinordata.org/ https://www.worldwildlife.org/projects/the-art-and-craft-of-systems-change

Join us as we talk with Veera Mahajan, the author of Unreported Crime, about her journey of surviving through and thriving after an abusive relationship. Her story is a reminder to never be afraid to start your life again on your own terms, no matter how difficult your situation might be.

In today's episode, Anna Rose (https://twitter.com/annarrose) and Nico Mohnblatt (https://twitter.com/nico_mnbl) interview Srinath Setty (https://twitter.com/srinathtv), Principal Researcher at Microsoft Research (https://twitter.com/msftresearch) and author of notable works such as Spartan, Nova, SuperNova, and HyperNova. This discussion covers Setty's early work and how this led to him working on SNARKs, folding schemes and sumcheck protocols, as well as his views on the future trajectory of the ZK space. Given the current chatter around Nova-style accumulation schemes, this interview offers a chance to explore the perspective of a key contributor behind these developments. Here's some additional links for this episode: Pepper Project Publications (https://www.pepper-project.org/publications.htm) Depot: Cloud storage with minimal trust by Mahajan, Setty, Lee, Clement, Alvisi, Dahlin, and Walfish (https://www.microsoft.com/en-us/research/wp-content/uploads/2016/02/depot-osdi10.pdf) Resolving the conflict between generality and plausibility in verified computation by Setty, Braun, Vu, Blumberg, Parno, and Walfish (https://eprint.iacr.org/2012/622.pdf) Proving the correct execution of concurrent services in zero-knowledge (extended version) by Setty, Angel, Gupta and Lee (https://eprint.iacr.org/2018/907.pdf) Replicated state machines without replicated execution by Lee, Nikitin and Setty (https://eprint.iacr.org/2020/195.pdf) Quadratic Span Programs and Succinct NIZKs without PCPs by Gennaro, Gentry, Parno and Raykova (https://eprint.iacr.org/2012/215.pdf) Pinocchio: Nearly Practical Verifiable Computation by Parno, Howell, Gentry and Raykova (https://eprint.iacr.org/2013/279.pdf) Incrementally Verifiable Computation or Proofs of Knowledge Imply Time/Space Efficiency by Valiant (https://iacr.org/archive/tcc2008/49480001/49480001.pdf) Succinct Non-Interactive Arguments via Linear Interactive Proofs by Bitansky, Chiesa, Ishai, Ostrovsky and Paneth (https://eprint.iacr.org/2012/718.pdf) Open VDF: Accelerating the Nova SNARK-based VDF Article (https://medium.com/supranational/open-vdf-accelerating-the-nova-snark-based-vdf-2d00737029bd) Episode 274: SNARKs: A Trilogy with Ariel Gabizon (https://zeroknowledge.fm/274-2/) ZK Study Club: Supernova Srinath Setty - MS Research (https://www.youtube.com/watch?v=ilrvqajkrYY) Check out the ZK Jobs Board here: ZK Jobs (https://jobsboard.zeroknowledge.fm/). Find your next job working in ZK! Zero-knowledge is changing the world and until now, building ZK applications meant learning new, chain-specific languages and complex cryptography. But no more! With SnarkyJS, the easiest to use zk SDK, developers can add the magic of zk to their apps using TypeScript! Whether you're targeting Mina (https://minaprotocol.com/), the leading zk-native blockchain, or off-chain applications, SnarkyJS from O(1) Labs (https://o1labs.org/) has you covered. With support for infinite recursion, in-browser proving, and so much more, the full power of zk is available to everyone. Visit snarkyjs.o1labs.org (snarkyjs.o1labs.org) to get started. If you like what we do: * Find all our links here! @ZeroKnowledge | Linktree (https://linktr.ee/zeroknowledge) * Subscribe to our podcast newsletter (https://zeroknowledge.substack.com) * Follow us on Twitter @zeroknowledgefm (https://twitter.com/zeroknowledgefm) * Join us on Telegram (https://zeroknowledge.fm/telegram) * Catch us on YouTube (https://zeroknowledge.fm/)

In this episode, we hear from Sudha Mahajan, a product executive with over 19 years of experience in digital media, e-commerce, marketplaces, generative and cognitive AI, and cloud technology. Sudha shares her career journey and offers advice to those who want to pursue a similar career path. She stresses the importance of being flexible and adapting to change, having a positive attitude, and finding inspiration in role models. Sudha also debunks a common myth about product management and shares her favorite books and resources. She emphasizes the importance of having principles and finding one's voice in the workplace, and the value of lifelong learning. Throughout the episode, Sudha shares her personal experiences and offers insightful quotes, including one from Mahatma Gandhi: "be the change you want to see in the world." What You'll Learn: Be flexible in your career path as the role you start with may take multiple shapes and forms. Attitude of optimism and being positive is crucial to succeeding in any career. Finding your voice and defining your principles is important in the beginning of your career. Resources Mentioned: Originals: How Non-Conformists Move the World by Adam Grant Culture Code by Daniel Coyle The 7 Habits of Highly Effective People by Sean Covey Contact Us: https://youtube.com/@aarnasnews https://www.instagram.com/aarnas_news/ nerdytechcash@gmail.com --- Support this podcast: https://podcasters.spotify.com/pod/show/aarna-sahu/support